Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Rita AssiHagop M KantarjianTapan Mahendra KadiaNaveen PemmarajuElias J JabbourNitin JainNaval G DaverZeev EstrovTaisuke UeharaTakashi OwaJorge E CortesGautam BorthakurPublished in: Cancer (2018)
The combination of indisulam with idarubicin and cytarabine yielded a 35% response rate in heavily pretreated patients with AML. With emerging data identifying the expression of DCAF15 (DDB1 and CUL4-associated factor 15) as a potential biomarker for activity, the combination of indisulam with idarubicin and cytarabine should be studied in a biomarker-driven trial or in patients who have splicing factor mutations. Cancer 2018;124:2758-65. © 2018 American Cancer Society. Cancer 2018;124:2758-2765. © 2018 American Cancer Society.
Keyphrases
- acute myeloid leukemia
- papillary thyroid
- squamous cell
- open label
- allogeneic hematopoietic stem cell transplantation
- high dose
- clinical trial
- poor prognosis
- lymph node metastasis
- squamous cell carcinoma
- radiation therapy
- study protocol
- end stage renal disease
- phase iii
- prognostic factors
- randomized controlled trial
- machine learning
- electronic health record
- childhood cancer
- binding protein
- deep learning
- solid state
- placebo controlled
- hodgkin lymphoma